MARKET

AGLE

AGLE

Aeglea Biotherap
NASDAQ
11.34
-0.91
-7.43%
Opening 10:47 10/02 EDT
OPEN
12.04
PREV CLOSE
12.25
HIGH
12.25
LOW
11.34
VOLUME
4.28K
TURNOVER
0
52 WEEK HIGH
39.00
52 WEEK LOW
2.660
MARKET CAP
45.90M
P/E (TTM)
-0.1587
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at AGLE last week (0925-0929)?
Weekly Report · 14h ago
WuXi Biologics Obligated To Pay A Service Fee And All Non-Cancellable Obligations Specified In Each Work Order, With Termination Possible Upon Completion Of Services Or With Prior Notice For Certain Reasons.
Benzinga · 09/25 20:17
Paragon Therapeutics, Inc. And WuXi Biologics Entered Into A Biologics Master Services Agreement, Which Was Later Transferred To Aeglea Biotherapeutics, Inc., Governing Development Activities And Manufacturing For The Company's SPY001 Program
Benzinga · 09/25 20:17
Weekly Report: what happened at AGLE last week (0918-0922)?
Weekly Report · 09/25 11:18
Weekly Report: what happened at AGLE last week (0911-0915)?
Weekly Report · 09/18 11:11
Aeglea Biotherapeutics (AGLE) Gets a Buy from Stifel Nicolaus
TipRanks · 09/14 02:05
Aeglea Biotherap: Current report
Press release · 09/09 00:03
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 09/07 13:06
More
About AGLE
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. It is focused on human enzyme therapeutics to treat people with rare metabolic diseases. Its product candidate is Pegtarviliase, a novel polyethylene glycol modified (PEGylated), human enzyme engineered to reduce elevated levels of total homocysteine circulating in the plasma. It has engineered pegtarviliase by directed mutagenesis of amino acids within the wild-type human cystathionine y-lyase enzyme (CGL). The Company’s second product candidate Pegzilarginase is a PEGylated, recombinant human arginase 1 that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase 1 Deficiency. It has engineered pegzilarginase with modifications that enhance arginine-degrading activity of the enzyme in human plasma. The Company is engaged in advancing inflammatory bowel disease (IBD) portfolio which consists of SPY001 and SPY002, antibody candidates.

Webull offers kinds of Aeglea Bio Therapeutics Inc stock information, including NASDAQ:AGLE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGLE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGLE stock methods without spending real money on the virtual paper trading platform.